Original Article

You have full text access to this OnlineOpen article

Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C

  1. M L Shiffman,
  2. C M Hofmann,
  3. E B Thompson,
  4. A Ferreira-Gonzalez,
  5. M J Contos,
  6. A Koshy,
  7. V A Luketic,
  8. A J Sanyal,
  9. A S Mills,
  10. C T Garrett

Article first published online: 30 DEC 2003

DOI: 10.1002/hep.510260335

Issue

Hepatology

Hepatology

Volume 26, Issue 3, pages 780–785, September 1997

Additional Information

How to Cite

Shiffman, M. L., Hofmann, C. M., Thompson, E. B., Ferreira-Gonzalez, A., Contos, M. J., Koshy, A., Luketic, V. A., Sanyal, A. J., Mills, A. S. and Garrett, C. T. (1997), Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology, 26: 780–785. doi: 10.1002/hep.510260335

Author Information

  1. Hepatology Section, Medical College of Virginia, Virginia Commonwealth University, Richmond 23298, USA

Publication History

  1. Issue published online: 30 DEC 2003
  2. Article first published online: 30 DEC 2003

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (239K)

References

  • 1
    Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC, Perrillo RP, Carey W, et al. Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter, randomized, controlled trial. N Eng J Med 1989; 321: 1501–1506.
  • 2
    DiBisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, Goodman Z, Banks SM, Hoofnagle JH. Recombinant interferon alfa therapy for chronic hepatitis C. N Eng J Med 1989; 321: 1506–1510.
  • 3
    Marcellin P, Boyer N, Giostra E, Degott C, Courouce AM, Degos F, Coppere H, Cales P, Couzigou P, Benhamou JP. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology 1991; 13: 393–397.
    Direct Link:
  • 4
    Causse X, Godinot H, Chevallier M, Chossegros P, Zoulim F, Ouzan D, Heyraud JP, Fontanges T, Albrecht J, Meschievitz C, Trepo C. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology 1991; 101: 497–502.
  • 5
    Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, Belussi F, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700–706.
  • 6
    Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, Couzigou P, Payen JL, Sajus M, Costa JM, Vidaud M Chaput JC and the multicenter study group. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Eng J Med 1995; 332: 1457–1462.
  • 7
    Shiffman ML, Hofmann CH, Luketic, VA, Sanyal AJ, Contos MA, Mills AS. Gradual reduction in interferon dose reduces the incidence of relapse in patients with chronic hepatitis C: results of a randomized controlled trial. Hepatology 1996; 24: 21–26.
    Direct Link:
  • 8
    Shindo M, Di Bisceglie AM, Cheung L, Shih WK, Cristiano K, Feinstone SM, Hoofnagle JH. Decrease in serum hepatitis C viral RNA during alpha-interferon therapy for chronic hepatitis C. Ann Intern Med 1991; 115: 700–704.
  • 9
    Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TN, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431–435.
    Direct Link:
  • 10
    Ferreira-Gonzalez A, Shiffman ML, Lofland DH, Langley MR, Gainey DW, Garrett CT. Assessing clinical utility of hepatitis C virus quantitative RT-PCR data. Implications for identification of responders among α-interferon treated patients. Mol Diagn 1996; 1: 109–120.
  • 11
    Gurakar A, Fagiuoli S, Faruki H, De Maria N, Balkan M, Van Thiel DH, Friedlander L. Utility of hepatitis C virus RNA determinations in hepatic tissue as an end point for interferon treatment of chronic hepatitis C. Hepatology 1995; 22: 109–1112.
    Direct Link:
  • 12
    McGuinness PH, Bishop GA, Painter DM, Chan R, McCaughan GW. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology 1996; 23: 676–687.
    Direct Link:
  • 13
    Gretch DR, Rosa C dela, Carithers RL Jr, Willson RA, Williams B, Corey L. Assessment of hepatitis C viremia using molecular amplification technologies: correlations and clinical implications. Ann Intern Med 1995; 123: 321–329.
  • 14
    Lau JY, Davis GL, Kniffen J, Quian KP, Urdea M, Chan C, Mizokami L, et al. Significance of hepatitis C virus RNA levels in chronic hepatitis. Lancet 1993; 341: 1501–1504.
  • 15
    Martinot-Peignoux M, Marcellin P, Pouteau M, Castelnau C, Boyer N, Poliquin M, Degott C, Descombes I, Le Breton V, Milotova V, Benhamou JP, Erlinger S. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995; 22: 1050–1056.
    Direct Link:
  • 16
    Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh, S, Hashimoto M, et al. Factors predictive of response to interferon- therapy in hepatitis C virus infection. Hepatology 1994; 19: 1088–1094.
    Direct Link:
  • 17
    Bellary S, Smith DG, Bankes P, Harris A, Shayiq R, Black M. High dose interferon -2b therapy for chronic hepatitis C: Open label study of the response and predictors of response. Am J Gastroenterol 1995; 90: 259–262.
  • 18
    Shiffman ML, Hofmann CM, Luketic VA, Thompson EB, Sanyal AJ. Treatment of chronic hepatitis C with escalating doses of interferon-2b increases both biochemical and virologic response [Abstract]. Hepatology 1995; 22: 152A.
  • 19
    Marcellin P, Pouteau M, Martinot-Peignoux M, Degos F, Duchatelle V, Boyer N, Lemonnier C, Degott C, Erlinger S, Benhamou JP. Lack of benefit of escalating dosage of interferon alfa in patients with chronic hepatitis C. Gastroenterology 1995; 109: 156–165.
  • 20
    Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, Wejstal R, Yun ZB, Weiland O. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with inter-feron-2b for 60 weeks. Hepatology 1994; 19: 280–285.
    Direct Link:
  • 21
    Saracco G, Rosina F, Abate M, Chiandussi L, Gallo V, Cerutti E, Di Napoli A, Solinas A, Deplano A, Tocco A. Long-term follow-up of patients with chronic hepatitis C treated with different doses of interferon-2b. Hepatology 1993; 18: 1300–1305.
    Direct Link:
  • 22
    Van Thiel DH, Friedlander L, Fagiuoli S, Wright H I, Irish W, Gavaler JS. Response to interferon therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410–415.
  • 23
    Bacon BR, Rebholz AE, Fried MW, Di Bisceglie AM. Beneficial effect of iron reduction therapy in patients with chronic hepatitis C who failed to respond to interferon therapy [Abstract]. Hepatology 1993; 18: 373A.
  • 24
    Andreone P, Cursaro C, Gramenzi A, Buzzi A, Miniero R, Sprovieri G, Gasbarrini. Alfa-interferon plus indomethacin combined therapy for non-responder patients with chronic hepatitis C [Abstract]. Hepatology 1993; 18: 221A.
  • 25
    Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812–817.
  • 26
    Lai MY, Kao JH, Yang PM, Wang JT, Chen PJ, Chan KW, Chu JS, Chen DS. Long term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology 1996; 111: 1307–1312.
  • 27
    Mutchnick MG, Ehrinpreis MN, Kinzie JL, Peleman RR. Prospectives on the treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and antiviral agents. Antivir Res 1994; 24: 245–57.
  • 28
    Angelico M, Gandin C, Pescarmona E, Rapicetta M, Del Vecchio C, Bini A, Spada E, Baroni CD, Capocaccia L. Recombinant interferon-α and ursodeoxycholic acid versus interferon-α alone in the treatment of chronic hepatitis C: a randomized clinical trial with long-term follow-up. Am J Gastroenterol 1995; 90: 263–269.
  • 29
    Delich P, Hofmann CM, Luketic VA, Purdum III PP, Sanyal AJ, Mills AS, Contos MJ, Shiffman ML. Treatment of chronic hepatitis C with ursodeoxycholic acid in patients who failed interferon therapy [abstract]. Gastroenterology 1995; 108: A1057.
  • 30
    Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, Hashimoto E, Lefkowitch JH, Ludwig J, Okuda K. The long-term pathological evolution of chronic hepatitis C. Hepatology 1996; 23: 1334–1340.
    Direct Link:
  • 31
    David E, Pucci A, Palladin D, Saracco G, Garello E, Pintus C, Rocca G, et al. Histologic changes in liver biopsy specimens produced by recombinant interferon α-2b therapy for chronic non-A, non-B viral hepatitis. Am J Clin Pathol 1992; 98: 397–401.
  • 32
    Castillo I, Bartolome J, Navas S, Gonzalez S, Herrero M, Carreno V. Virologic and biochemical long-term follow-up of patients with chronic hepatitis C treated with interferon. Hepatology 1994; 19: 241–275.
    Direct Link:
  • 33
    Suou T, Hosho K, Kishimoto Y, Horie Y, Kawasaki H. Long-term decrease in serum N-terminal propeptide of type III procollagen in patients with chronic hepatitis C treated with interferon alfa. Hepatology 1995; 22: 426–431.
    Direct Link:
Get PDF (239K)